Ezetimibe And Simvastatin

Coronary heart disease, prophylaxis of cardiovascular event, Diabetes + 11 more

Treatment

19 FDA approvals

20 Active Studies for Ezetimibe And Simvastatin

What is Ezetimibe And Simvastatin

Simvastatin

The Generic name of this drug

Treatment Summary

Simvastatin, also known as Zocor, is a medication used to lower cholesterol levels and reduce the risk of cardiovascular disease. It belongs to a class of drugs called statins, which work by blocking a particular enzyme in the liver that is involved in cholesterol production. Statins are recommended for people with moderate to high risk of developing cardiovascular disease, like those with type 2 diabetes. Simvastatin is one of the most commonly prescribed statin drugs, along with atorvastatin, pravastatin, rosuvastatin, fluvastatin, and lovastatin. Studies have shown that stat

Zocor

is the brand name

image of different drug pills on a surface

Ezetimibe And Simvastatin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zocor

Simvastatin

1991

620

Approved as Treatment by the FDA

Simvastatin, otherwise called Zocor, is approved by the FDA for 19 uses like Diabetes Mellitus and Homozygous Familial Hypercholesterolemia .

Diabetes Mellitus

Homozygous Familial Hypercholesterolemia

Used to treat Homozygous Familial Hypercholesterolaemia (HoFH) in combination with Ezetimibe

Hypercholesterolemia

Used to treat Heterozygous Familial Hypercholesterolemia (HeFH) in combination with Ezetimibe

Mixed Hyperlipidemia

Used to treat Mixed Hyperlipidemia in combination with Ezetimibe

Diet

Used to treat Diet in combination with Ezetimibe

Lipid-Lowering Therapy

Used to treat Lipid-Lowering Therapy in combination with Ezetimibe

Homozygous Familial Hypercholesterolaemia (HoFH)

Used to treat Homozygous Familial Hypercholesterolaemia (HoFH) in combination with Ezetimibe

history of stroke or other cerebrovascular disease cardiovascular event

prophylaxis of cardiovascular event

Heterozygous Familial Hypercholesterolemia (HeFH)

Used to treat Heterozygous Familial Hypercholesterolemia (HeFH) in combination with Ezetimibe

Physical Activity

Used to treat Exercise in combination with Ezetimibe

history of coronary heart disease cardiovascular event

Cardiovascular Events

cholesterol

Helps manage High Cholesterol

Peripheral Vascular Disease Patient

Diabetes

Coronary heart disease

Peripheral Vascular Disease

Cerebrovascular Disorders

Effectiveness

How Ezetimibe And Simvastatin Affects Patients

Simvastatin is a medicine used to lower levels of total cholesterol, "bad" low-density lipoprotein (LDL) cholesterol, non-high density lipoprotein (non-HDL) cholesterol, triglycerides (TG), and apolipoprotein B (apoB) in the blood. High levels of these things are linked to a higher risk of heart disease and stroke. It also increases levels of "good" high-density lipoprotein (HDL) cholesterol, which is linked to a lower risk of cardiovascular disease. Taking Simvastatin has been shown to reduce the risk of cardiovascular disease and

How Ezetimibe And Simvastatin works in the body

Simvastatin works by blocking an enzyme in the liver that helps create cholesterol. When this enzyme is blocked, the liver takes up less cholesterol from the blood and makes less of it. Simvastatin also has additional benefits, including helping stabilize and protect blood vessels, reducing oxidative stress and inflammation, and preventing clot formation. Additionally, Simvastatin binds to a protein that helps regulate the movement of white blood cells and helps prevent them from getting too active.

When to interrupt dosage

The measure of Ezetimibe And Simvastatin is reliant upon the diagnosed condition, including Hypercholesterolemia, Diet and Type 2 Diabetes. The extent of dosage varies as per the administration technique outlined in the table beneath.

Condition

Dosage

Administration

Mixed Hyperlipidemia

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Peripheral Vascular Disease

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Coronary heart disease

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

prophylaxis of cardiovascular event

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Diabetes

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Cardiovascular Events

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Physical Activity

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Type 2 Diabetes

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

cholesterol

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Diet

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Lipid-Lowering Therapy

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Hypercholesterolemia

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Cerebrovascular Disorders

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Homozygous Familial Hypercholesterolemia

, 80.0 mg, 10.0 mg, 20.0 mg, 40.0 mg, 5.0 mg, 20.0 mg/mL, 40.0 mg/mL, 4.0 mg/mL

Oral, Tablet, film coated - Oral, , Tablet, film coated, Tablet, Tablet - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Suspension, Suspension - Oral, Tablet, orally disintegrating, Tablet, orally disintegrating - Oral, Tablet, coated, Tablet, coated - Oral, Periarticular, Tablet, film coated - Periarticular

Warnings

Ezetimibe And Simvastatin Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Liver Diseases

Do Not Combine

There are 20 known major drug interactions with Ezetimibe And Simvastatin.

Common Ezetimibe And Simvastatin Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The serum concentration of Abemaciclib can be increased when it is combined with Simvastatin.

Amitriptyline

Major

The metabolism of Amitriptyline can be decreased when combined with Simvastatin.

Amoxapine

Major

The metabolism of Amoxapine can be decreased when combined with Simvastatin.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Simvastatin.

Axitinib

Major

The serum concentration of Axitinib can be increased when it is combined with Simvastatin.

image of a doctor in a lab doing drug, clinical research

Ezetimibe And Simvastatin Novel Uses: Which Conditions Have a Clinical Trial Featuring Ezetimibe And Simvastatin?

Presently, there are 756 active studies investigating the potential of Ezetimibe and Simvastatin to ameliorate Cerebrovascular Disorders, Type 2 Diabetes and Physical Activity.

Condition

Clinical Trials

Trial Phases

Type 2 Diabetes

167 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1

Diabetes

74 Actively Recruiting

Phase 1, Not Applicable, Phase 4, Phase 2, Phase 3

Homozygous Familial Hypercholesterolemia

2 Actively Recruiting

Phase 3

cholesterol

4 Actively Recruiting

Phase 3, Not Applicable

prophylaxis of cardiovascular event

0 Actively Recruiting

Physical Activity

24 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Hypercholesterolemia

4 Actively Recruiting

Phase 1, Phase 3

Lipid-Lowering Therapy

0 Actively Recruiting

Cerebrovascular Disorders

2 Actively Recruiting

Phase 1, Not Applicable

Diet

5 Actively Recruiting

Not Applicable, Phase 1

Cardiovascular Events

4 Actively Recruiting

Not Applicable

Coronary heart disease

0 Actively Recruiting

Mixed Hyperlipidemia

0 Actively Recruiting

Peripheral Vascular Disease

6 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 4, Phase 3

Ezetimibe And Simvastatin Reviews: What are patients saying about Ezetimibe And Simvastatin?

5

Patient Review

11/8/2009

Ezetimibe And Simvastatin for High Cholesterol

I've been on cholesterol medication for 35 years now, and this is by far the best one I've tried. My readings are great - around 115 - and my LDL and HDL are well within the healthy range.

5

Patient Review

9/27/2021

Ezetimibe And Simvastatin for High Cholesterol

I've been taking Vytorin for ten years now and it's the only statin that doesn't give me muscle pains. My levels stay well below average, and I haven't experienced any side effects that I know of. Although, sometimes it's hard to fall asleep at night, but I'm not sure if that has anything to do with the medication or not.

2.7

Patient Review

3/28/2011

Ezetimibe And Simvastatin for Combined High Blood Cholesterol and Triglyceride Level

I'm finding it hard to sleep, does anyone else have this problem?

2.3

Patient Review

11/12/2008

Ezetimibe And Simvastatin for High Cholesterol

I developed pain across both of my shoulders after starting to take this medication. The pain developed within two weeks.

2.3

Patient Review

4/1/2008

Ezetimibe And Simvastatin for High Cholesterol

I was experiencing extreme muscle pain in my chest, right arm and back.

2

Patient Review

9/29/2016

Ezetimibe And Simvastatin for High Cholesterol

I experienced a lot of stomach pain and gas while taking this pill, only after 12 days.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ezetimibe and simvastatin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can you take ezetimibe and simvastatin together?

"You may be at an increased risk for muscle injury and kidney problems if you take these medications with ezetimibe and simvastatin."

Answered by AI

What class of drug is ezetimibe and simvastatin?

"Ezetimibe is a cholesterol-lowering medication that can be used alone or in combination with a statin."

Answered by AI

What is the best time to take ezetimibe simvastatin?

"There is no time of day that is better to take ezetimibe, as it works the same whether taken in the morning, afternoon, or evening. Ezetimibe is taken once a day at the same time each day and can be taken with or without food."

Answered by AI

Why is simvastatin combined with ezetimibe?

"This medicine is a combination of two drugs, Ezetimibe and Simvastatin, which are used together with a proper diet to treat high cholesterol and triglyceride levels in the blood. This medicine may help prevent heart attacks and strokes by keeping blood vessels clear."

Answered by AI

Clinical Trials for Ezetimibe And Simvastatin

Image of Brigham and Women's Hospital in Boston, United States.

Rosuvastatin for Cancer-Associated Blood Clots

18+
All Sexes
Boston, MA

Patients with cancer are at high risk for life-threatening venous thromboembolism (VTE) yet rarely receive anticoagulant prophylaxis due to bleeding risks. Thus, effective prophylaxis in oncology requires a method to reduce VTE without increasing hemorrhage. The primary aim of the Statin Therapy to Prevent Cancer Associated Venous Thromboembolism (STAT-CAT) trial is to test whether rosuvastatin 20 mg daily for 12 months compared to placebo can safely prevent VTE in patients with newly diagnosed or recently relapsed cancer who are at increased thrombotic risk, are not planned to be anticoagulated, and who do not otherwise take statin therapy.

Phase 4
Waitlist Available

Brigham and Women's Hospital (+1 Sites)

Image of Duke Center for Living in Durham, United States.

Glucagon for Diabetes

18 - 45
All Sexes
Durham, NC

This study examines how glucagon works to regulate glucose metabolism, based on new findings that suggest glucagon signaling in the liver has more than one role, and that these multiple roles can be opposing in nature. Understanding this biology provides an opportunity to develop new generations of glucagon-based drugs that target specific pathways, making them more effective at controlling blood glucose. Participants will complete paired, 5-hour hyperinsulinemic glucose clamp visits in which they receive either glucagon or saline infusions while blood glucose is maintained and frequent blood samples are collected. The primary focus is whether coordinated glucagon and insulin signaling enhances hepatic insulin sensitivity.

Phase 1 & 2
Waitlist Available

Duke Center for Living

David D'Alessio, MD

Have you considered Ezetimibe And Simvastatin clinical trials?

We made a collection of clinical trials featuring Ezetimibe And Simvastatin, we think they might fit your search criteria.
Go to Trials
Image of NYU Langone Health in New York, United States.

Adaptive Dietary Intervention for Type 2 Diabetes

18+
All Sexes
New York, NY

The investigators will examine the feasibility, acceptability, and effect of an adaptive dietary intervention over 24 weeks (12-week intervention, 12-week follow-up) among Asian Americans with Type 2 diabetes. Participants (N=120; 60 Chinese Americans and 60 Vietnamese Americans) will be 2:1 randomized to one of two arms: adaptive dietary intervention or standard of care (SC). The intervention will begin with continued glucose monitoring (CGM) use only during weeks 0-4. At week 4, participants who achieve the glycemic control goal (at least an 8% increase in time in range \[TIR\] from baseline) will continue with the CGM alone during weeks 4-12 ("CGM Alone"); otherwise, culturally and linguistically adapted glucose excursion minimization (GEM) will be augmented with CGM ("CGM-GEM").

Waitlist Available
Has No Placebo

NYU Langone Health

Yaguang Zheng, PhD, RN

Have you considered Ezetimibe And Simvastatin clinical trials?

We made a collection of clinical trials featuring Ezetimibe And Simvastatin, we think they might fit your search criteria.
Go to Trials
Image of UConn Health in Farmington, United States.

Digital Exercise Prescription Tool for Cardiovascular Disease

18 - 64
All Sexes
Farmington, CT

The investigators will conduct a feasibility and pilot efficacy randomized controlled trial to test the usability and user satisfaction of an evidence-based digital health tool the investigators developed for physicians to use to Prioritize Personalize Prescribe EXercise (P3-EX) to patients with cardiovascular disease (CVD) risk factors. The investigators will recruit 24 physicians from two local hospitals in CT, USA. Physicians will recruit two patients each (N=48) having CVD risk factors. Physicians will deliver a P3-EX exercise prescription (ExRx) to one of their patients (n=24) and the American College of Sports Medicine Physical Activity Vital Sign (ACSM-PAVS) ExRx to the other (n=24) in a random sequence crossover design. Physicians and patients will rate the feasibility and acceptability of each method using validated questionnaires. Patients will perform their prescribed ExRx for 12 weeks and complete a self-report exercise diary to monitor exercise adherence with virtual oversight from University of Connecticut (UConn) Graduate Research Assistants. Before and after the exercise intervention, the investigators will measure patient CVD risk factors and physical activity (PA) levels via accelerometry. The primary aim is to evaluate the feasibility and acceptability of P3-EX for physicians to use to prescribe exercise to patients with CVD risk factors, and the secondary aim is to explore the preliminary efficacy of P3-EX to improve patient CVD risk factors, PA levels, and exercise adherence. The investigators hypothesize P3-EX will be feasible for physicians to use to prescribe customized exercise routines for patients with CVD risk factors, and physicians and patients will be satisfied with P3-EX.

Waitlist Available
Has No Placebo

UConn Health (+2 Sites)

Linda S Pescatello, PhD

Image of University of California, Los Angeles in Los Angeles, United States.

Tailored DPP for Prediabetes

17 - 25
All Sexes
Los Angeles, CA

The goal of this study is to enhance reach and uptake of diabetes prevention among young adults, with a focus on recruiting underserved and high-need students who face additional challenges, including food and financial insecurity. The specific aims are: Aim 1 - Evaluate the efficacy of an AYA-tailored version of the UC DPP for mitigating type 2 diabetes risk (i.e., weight change) in a pre/post pilot trial. The investigators hypothesize that the AYA-tailored intervention will be effective at producing 5% weight loss from baseline to program completion (at 9-months). Aim 2 - Assess the feasibility and acceptability of an AYA-tailored version of the UC DPP program. The investigators hypothesize that it will be feasible to recruit the desired number of participants given proposed innovative outreach strategies, and that the AYA-tailored intervention will be deemed acceptable to participants both qualitatively and in regards to their retention in the program at rates similar to the larger UC DPP. The investigators will recruit 80 UCLA undergraduate students. Participants will be asked to complete a brief screening online form to assess eligibility and to collect contact information. The PI and/or Research Assistants (RAs) will reach out to eligible participants to obtain informed consent and enroll them in the pilot trial. The investigators will randomize participants to the tailored DPP cohort vs control cohort. Control participants will be offered the opportunity to participate in the tailored DPP in the following academic year. The tailored DPP intervention will be online and asynchronously. Participants will be asked to complete the intervention lessons on their own time. Each lesson typically takes on average 15 minutes to complete. Control group will receive each intervention materials via e-mail for participants to review on their own time and will receive acceptability surveys. The interventions for the control group will be remote. A research assistant will meet with control participants via Zoom to explain the intervention materials. Control group will receive access to a study habits intervention, alcohol use intervention, and financial literacy intervention. At the end of each quarter (Fall, Winter, and Spring), both control and intervention participants will receive an email with a unique link to a brief REDCap survey to ascertain acceptability of sessions/lessons. Furthermore, participants will complete baseline and 9-month follow-up assessments. Participants will complete a 30 minute questionnaire and height/weight measurements will be collected by a RA. Participants will be asked to self-report weight and physical activity at the end of the fall and winter quarter; data will be collected via brief REDCap survey.

Recruiting
Has No Placebo

University of California, Los Angeles

Lauren E Wisk, PhD

Have you considered Ezetimibe And Simvastatin clinical trials?

We made a collection of clinical trials featuring Ezetimibe And Simvastatin, we think they might fit your search criteria.
Go to Trials